A target that seemed impossible to hit
For 40 years, KRAS has been one of the most infamous names in cancer research. It is a gene that, when mutated, helps fuel many of the worst cancers. Pancreatic cancer. Lung cancer. Colon cancer.
Doctors have known this for ages. The trouble was designing a drug that could safely block it. KRAS was long called "undruggable."
A few recent drugs finally cracked one specific KRAS mutation called G12C. But the most common KRAS mutation in pancreatic cancer, called G12D, remained out of reach. Pancreatic cancer patients with the G12D mutation, which means nearly half of all pancreatic patients, had no targeted therapy options.
Until now.
Pancreatic cancer is one of the deadliest common cancers. Five-year survival remains in the single digits for most patients. Lung cancer with the G12D mutation, though less common, is also tough to treat.
Any drug that targets G12D directly is big news. It opens a door that has been locked since cancer researchers first started knocking.
Traditional cancer drugs either block a protein or attack cells that divide quickly. Neither worked well for KRAS.
The new approach is different. Setidegrasib is what scientists call a "protein degrader." Instead of blocking KRAS, it marks the mutated protein for destruction. The body's own cellular recycling system then comes along and destroys it.
That is like hiring a demolition crew instead of trying to build a wall around the problem.
How it works, in plain English
Imagine the mutated KRAS protein as a stuck piece of junk inside a cancer cell. Blocking it was like trying to patch over the junk. The cell still had the junk around, just covered up.
Setidegrasib acts more like a sticker that says "trash me." Your cells have a built-in cleanup system that notices those stickers and pulls the tagged objects into a recycling unit. The junk disappears. The cell can no longer use it.
When a cancer cell depends on that junk protein to survive, removing it is devastating for the cancer.
The study snapshot
Researchers enrolled 203 patients with advanced cancers carrying the G12D mutation. Most had either non-small cell lung cancer (NSCLC) or pancreatic cancer. All had already tried other treatments and seen their disease progress.
Setidegrasib was given by IV once a week at varying doses. The team tracked safety, tumor response, and how long patients lived without their cancer growing.
A dose of 600 mg was eventually selected as the phase 2 dose. 76 patients received that dose.
Here's what they found
Results in lung cancer were especially striking. Of 45 NSCLC patients who received 600 mg, 36 percent had their tumors shrink significantly. Median time before the cancer grew again was 8.3 months. An estimated 59 percent were still alive at 12 months.
Pancreatic cancer results were more modest but still meaningful. Of 21 pancreatic cancer patients, 24 percent had tumors shrink. Median time before progression was 3 months. Median overall survival was 10.3 months.
Those numbers may seem small out of context. But for patients with advanced pancreatic cancer whose disease had already grown through other treatments, a drug that extends life by months is a real win.
This is where things get interesting.
Side effects were notable but generally manageable. Treatment-related adverse events happened in 93 percent of patients. About 4 in 10 had severe side effects. The most common issues were infusion-related reactions and nausea.
Only 2 patients stopped the drug because of side effects. That is remarkably low for a new cancer drug.
How the researchers read it
The authors describe setidegrasib as the first-in-class degrader of KRAS G12D. They see it as a meaningful step forward for patients who had no targeted options before.
They also flag that many patients still progressed. This drug is not yet a cure. Combinations with other therapies will likely be needed to push results further.
If you or a loved one has advanced pancreatic cancer or lung cancer, ask whether the tumor has been tested for the KRAS G12D mutation. Genetic testing of tumors is now standard in many centers.
If the mutation is present, ask about clinical trials testing setidegrasib and similar drugs. Approval is still pending, but access through trials is often available.
For patients whose tumors do not carry this mutation, the news is still meaningful. It shows that previously untouchable cancers can be brought within reach with new technology. More drugs like this are on the way.
The limits
This was a phase 1 trial. Results need to be confirmed in larger, controlled phase 2 and phase 3 studies.
The follow-up was relatively short. How long responses last and whether drug resistance will emerge are open questions.
The drug is given IV weekly, which is a commitment for patients. Future versions may aim for less frequent dosing.
Phase 2 trials are already planned using the 600 mg dose. Combination trials will test setidegrasib alongside chemotherapy or immunotherapy.
Researchers are also developing similar degraders for other tough KRAS mutations and for other "undruggable" proteins in cancer. The era of designing drugs that destroy targets, not just block them, is just beginning.
